The promiscuous binding of pharmaceutical drugs and their transporter-mediated uptake into cells: what we (need to) know and how we can do so.

[1]  H. Schwan.  Electrical properties of tissue and cell suspensions. , 1957, Advances in biological and medical physics.

[2]  P. Seeman,et al.  The membrane actions of anesthetics and tranquilizers. , 1972, Pharmacological reviews.

[3]  Alan Mellors,et al.  The haldane relationship enzymes & equilibrium , 1976 .

[4]  A. Cornish-Bowden.  Fundamentals of Enzyme Kinetics , 1979 .

[5]  V A Levin,et al.  Relationship of octanol/water partition coefficient and molecular weight to rat brain capillary permeability. , 1980, Journal of medicinal chemistry.

[6]  D. Kell,et al.  The passive electrical properties of biological systems: their significance in physiology, biophysics and biotechnology. , 1987, Physics in medicine and biology.

[7]  Douglas B. Kell,et al.  Dielectric permittivity of microbial suspensions at radio frequencies: a novel method for the real-time estimation of microbial biomass , 1987 .

[8]  T. Keleti.  Basic Enzyme Kinetics , 1988 .

[9]  A. Fairlamb,et al.  Trypanothione is the primary target for arsenical drugs against African trypanosomes. , 1989, Proceedings of the National Academy of Sciences of the United States of America.

[10]  T. Walle,et al.  Stereoselective uptake of atenolol into storage granules isolated from PC12 cells. , 1989, The Journal of pharmacology and experimental therapeutics.

[11]  B. Dujon,et al.  The complete DNA sequence of yeast chromosome III , 1992, Nature.

[12]  A. Fairlamb,et al.  Arsenical-resistant trypanosomes lack an unusual adenosine transporter , 1993, Nature.

[13]  D. Thwaites,et al.  Transepithelial glycylsarcosine transport in intestinal Caco-2 cells mediated by expression of H(+)-coupled carriers at both apical and basal membranes. , 1993, The Journal of biological chemistry.

[14]  Alan Chalmers,et al.  What is this thing called science? - an assessment of the nature and status of science and its methods (2. ed.) , 1977, UQP nonfiction.

[15]  B. Barrell,et al.  Life with 6000 Genes , 1996, Science.

[16]  R. Moellering,et al.  Antimicrobial-drug resistance. , 1996, The New England journal of medicine.

[17]  A. Fersht.  Structure and mechanism in protein science , 1998 .

[18]  P. Corey,et al.  Incidence of Adverse Drug Reactions in Hospitalized Patients , 2012 .

[19]  P. Brick,et al.  Structural basis for the inhibition of firefly luciferase by a general anesthetic. , 1998, Biophysical journal.

[20]  V. Ganapathy,et al.  Cloning and Functional Characterization of a Potential-sensitive, Polyspecific Organic Cation Transporter (OCT3) Most Abundantly Expressed in Placenta* , 1998, The Journal of Biological Chemistry.

[21]  M. Trush,et al.  Diphenyleneiodonium, an NAD(P)H oxidase inhibitor, also potently inhibits mitochondrial reactive oxygen species production. , 1998, Biochemical and biophysical research communications.

[22]  R. Kaminsky,et al.  A nucleoside transporter from Trypanosoma brucei involved in drug resistance. , 1999, Science.

[23]  V. Sasseville,et al.  A Novel Human Hepatic Organic Anion Transporting Polypeptide (OATP2) , 1999, The Journal of Biological Chemistry.

[24]  Y. Kanai,et al.  Transport properties of nonsteroidal anti-inflammatory drugs by organic anion transporter 1 expressed in Xenopus laevis oocytes. , 1999, Molecular pharmacology.

[25]  Transport of [3H]losartan across isolated perfused rabbit proximal tubule. , 1999, The Journal of pharmacology and experimental therapeutics.

[26]  T. Andersson,et al.  Characterization of binding properties to human P-glycoprotein: development of a [3H]verapamil radioligand-binding assay. , 1999, The Journal of pharmacology and experimental therapeutics.

[27]  E. Holtzman,et al.  Molecular cloning and characterization of two novel human renal organic anion transporters (hOAT1 and hOAT3). , 1999, Biochemical and biophysical research communications.

[28]  D. Gründemann,et al.  Selective substrates for non-neuronal monoamine transporters. , 1999, Molecular pharmacology.

[29]  Y. Kanai,et al.  Transport of ochratoxin A by renal multispecific organic anion transporter 1. , 1998, The Journal of pharmacology and experimental therapeutics.

[30]  S. Kano.  [Drug resistant malaria]. , 2003, Nihon rinsho. Japanese journal of clinical medicine.

[31]  M. Rowland,et al.  Modulation of the permeability of H2 receptor antagonists cimetidine and ranitidine by P-glycoprotein in rat intestine and the human colonic cell line Caco-2. , 1999, The Journal of pharmacology and experimental therapeutics.

[32]  M. Lazdunski,et al.  Inhalational anesthetics activate two-pore-domain background K+ channels , 1999, Nature Neuroscience.

[33]  V. Ganapathy,et al.  Structural and functional characteristics and tissue distribution pattern of rat OCTN1, an organic cation transporter, cloned from placenta. , 2000, Biochimica et biophysica acta.

[34]  R. Evers,et al.  Interactions of the human multidrug resistance proteins MRP1 and MRP2 with organic anions. , 2000, Molecular pharmacology.

[35]  T. Cihlar,et al.  Nonsteroidal anti-inflammatory drugs efficiently reduce the transport and cytotoxicity of adefovir mediated by the human renal organic anion transporter 1. , 2000, The Journal of pharmacology and experimental therapeutics.

[36]  H. Saito,et al.  Interaction and transport of thiazide diuretics, loop diuretics, and acetazolamide via rat renal organic anion transporter rOAT1. , 2000, The Journal of pharmacology and experimental therapeutics.

[37]  K. Bleasby,et al.  The organic cation transporter OCT2 mediates the uptake of β‐adrenoceptor antagonists across the apical membrane of renal LLC‐PK1 cell monolayers , 2000, British journal of pharmacology.

[38]  M. Sanguinetti,et al.  A structural basis for drug-induced long QT syndrome. , 2000, Proceedings of the National Academy of Sciences of the United States of America.

[39]  I. Rusyn,et al.  Diphenyleneiodonium sulfate, an NADPH oxidase inhibitor, prevents early alcohol-induced liver injury in the rat. , 2001, American journal of physiology. Gastrointestinal and liver physiology.

[40]  Y. Kanai,et al.  Identification and characterization of human organic anion transporter 3 expressing predominantly in the kidney. , 2001, Molecular pharmacology.

[41]  Marilyn Roberts,et al.  Tetracycline Antibiotics: Mode of Action, Applications, Molecular Biology, and Epidemiology of Bacterial Resistance , 2001, Microbiology and Molecular Biology Reviews.

[42]  D B Kell,et al.  Genomic computing. Explanatory analysis of plant expression profiling data using machine learning. , 2001, Plant physiology.

[43]  K. Jung,et al.  Characterization of ochratoxin A transport by human organic anion transporters. , 2001, Life sciences.

[44]  J. Carlton,et al.  Conservation of a novel vacuolar transporter in Plasmodium species and its central role in chloroquine resistance of P. falciparum. , 2001, Current opinion in microbiology.

[45]  H. D. de Koning.  Uptake of pentamidine in Trypanosoma brucei brucei is mediated by three distinct transporters: implications for cross-resistance with arsenicals. , 2001, Molecular pharmacology.

[46]  T. Ideker,et al.  A new approach to decoding life: systems biology. , 2001, Annual review of genomics and human genetics.

[47]  J. Markowitz,et al.  In vitro P-glycoprotein affinity for atypical and conventional antipsychotics. , 2002, Life sciences.

[48]  W. Crumb,et al.  Three-dimensional quantitative structure-activity relationship for inhibition of human ether-a-go-go-related gene potassium channel. , 2002, The Journal of pharmacology and experimental therapeutics.

[49]  G. Tegos,et al.  Multidrug Pump Inhibitors Uncover Remarkable Activity of Plant Antimicrobials , 2002, Antimicrobial Agents and Chemotherapy.

[50]  Yuichi Sugiyama,et al.  Involvement of Organic Cation Transporter 1 in Hepatic and Intestinal Distribution of Metformin , 2002, Journal of Pharmacology and Experimental Therapeutics.

[51]  H. Kitano,et al.  Computational systems biology , 2002, Nature.

[52]  A. Enomoto,et al.  Role of human organic anion transporter 4 in the transport of ochratoxin A. , 2002, Biochimica et biophysica acta.

[53]  A. Enomoto,et al.  Interactions of Human Organic Anion Transporters and Human Organic Cation Transporters with Nonsteroidal Anti-Inflammatory Drugs , 2002, Journal of Pharmacology and Experimental Therapeutics.

[54]  T. Buzan.  How to Mind Map , 2002 .

[55]  H. Kitano.  Systems Biology: A Brief Overview , 2002, Science.

[56]  P. Neuvonen,et al.  Drug-related deaths in a university central hospital , 2002, European Journal of Clinical Pharmacology.

[57]  M. Yasui,et al.  Aquaporin Water Channels , 2004 .

[58]  Y. Tanigawara,et al.  Interaction of digoxin with antihypertensive drugs via MDR1. , 2002, Life sciences.

[59]  C. Clayton,et al.  Overexpression of the putative thiol conjugate transporter TbMRPA causes melarsoprol resistance in Trypanosoma brucei , 2002, Molecular microbiology.

[60]  H. Endou,et al.  Characterization of Methotrexate Transport and Its Drug Interactions with Human Organic Anion Transporters , 2002, Journal of Pharmacology and Experimental Therapeutics.

[61]  Ronald W. Davis,et al.  Functional profiling of the Saccharomyces cerevisiae genome , 2002, Nature.

[62]  Guri Giaever,et al.  A chemical genomics approach to understanding drug action. , 2003, Trends in pharmacological sciences.

[63]  L. Hood.  Systems biology: integrating technology, biology, and computation , 2003, Mechanisms of Ageing and Development.

[64]  A. Camm,et al.  Relationships between preclinical cardiac electrophysiology, clinical QT interval prolongation and torsade de pointes for a broad range of drugs: evidence for a provisional safety margin in drug development. , 2003, Cardiovascular research.

[65]  M. Ouellette,et al.  Functional Cloning of the Miltefosine Transporter , 2003, Journal of Biological Chemistry.

[66]  Andreas Rolfs,et al.  The ABCs of solute carriers: physiological, pathological and therapeutic implications of human membrane transport proteins , 2004, Pflügers Archiv.

[67]  Yu Zong Chen,et al.  Drug Adverse Reaction Target Database (DART) , 2003, Drug safety.

[68]  Matthew R. Redinbo,et al.  Structural basis of heroin and cocaine metabolism by a promiscuous human drug-processing enzyme , 2003, Nature Structural Biology.

[69]  B. Fermini,et al.  The impact of drug-induced QT interval prolongation on drug discovery and development , 2003, Nature Reviews Drug Discovery.

[70]  J. Sands.  Mammalian urea transporters. , 2003, Annual review of physiology.

[71]  M. Romero,et al.  The SLC4 family of HCO3− transporters , 2004, Pflügers Archiv.

[72]  Dragos Horvath,et al.  Predicting ADME properties and side effects: the BioPrint approach. , 2003, Current opinion in drug discovery & development.

[73]  Peter J. Meier,et al.  Organic anion transporting polypeptides of the OATP/SLC21 family: phylogenetic classification as OATP/SLCO superfamily, new nomenclature and molecular/functional properties , 2004, Pflügers Archiv.

[74]  G. Burckhardt,et al.  Transport of cimetidine by flounder and human renal organic anion transporter 1. , 2003, American journal of physiology. Renal physiology.

[75]  W. Tanner,et al.  Specific lipid requirements of membrane proteins--a putative bottleneck in heterologous expression. , 2003, Biochimica et biophysica acta.

[76]  H. Vromans,et al.  Caco-2 permeability, P-glycoprotein transport ratios and brain penetration of heterocyclic drugs. , 2003, International journal of pharmaceutics.

[77]  W. Sadee,et al.  Intestinal membrane transport of drugs and nutrients: genomics of membrane transporters using expression microarrays. , 2004, European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences.

[78]  N. Franks,et al.  The TREK K2P channels and their role in general anaesthesia and neuroprotection. , 2004, Trends in pharmacological sciences.

[79]  B. Roth,et al.  Magic shotguns versus magic bullets: selectively non-selective drugs for mood disorders and schizophrenia , 2004, Nature Reviews Drug Discovery.

[80]  Gregory W. Kauffman,et al.  Physicochemical Features of the hERG Channel Drug Binding Site* , 2004, Journal of Biological Chemistry.

[81]  S. Sasaki,et al.  Molecular mechanisms and drug development in aquaporin water channel diseases: aquaporin superfamily (superaquaporins): expansion of aquaporins restricted to multicellular organisms. , 2004, Journal of pharmacological sciences.

[82]  Claude Roques,et al.  Correlation Between Oral Drug Absorption in Humans, and Apparent Drug Permeability in TC-7 Cells, A Human Epithelial Intestinal Cell Line: Comparison with the Parental Caco-2 Cell Line , 1998, Pharmaceutical Research.

[83]  S. Ekins.  Predicting undesirable drug interactions with promiscuous proteins in silico. , 2004, Drug discovery today.

[84]  B. Palsson,et al.  The evolution of molecular biology into systems biology , 2004, Nature Biotechnology.

[85]  Gordon L. Amidon,et al.  Comparison of Human Duodenum and Caco-2 Gene Expression Profiles for 12,000 Gene Sequences Tags and Correlation with Permeability of 26 Drugs , 2002, Pharmaceutical Research.

[86]  Seeing the light: protein theories of general anesthesia. 1984. , 2004, Anesthesiology.

[87]  Antony D'Emanuele,et al.  The use of a dendrimer-propranolol prodrug to bypass efflux transporters and enhance oral bioavailability. , 2004, Journal of controlled release : official journal of the Controlled Release Society.

[88]  D. Kell,et al.  On the dielectrically observable consequences of the diffusional motions of lipids and proteins in membranes , 1985, European Biophysics Journal.

[89]  Munir Pirmohamed,et al.  Active transport of imatinib into and out of cells: implications for drug resistance. , 2004, Blood.

[90]  Bryan L Roth,et al.  Screening the receptorome to discover the molecular targets for plant-derived psychoactive compounds: a novel approach for CNS drug discovery. , 2004, Pharmacology & therapeutics.

[91]  M. Pirmohamed,et al.  Adverse drug reactions as cause of admission to hospital: prospective analysis of 18 820 patients , 2004, BMJ : British Medical Journal.

[92]  Paul D. Martin,et al.  Rosuvastatin pharmacokinetics in heart transplant recipients administered an antirejection regimen including cyclosporine , 2004, Clinical pharmacology and therapeutics.

[93]  T. Abe,et al.  Comparative Inhibitory Effects of Different Compounds on Rat Oatp1 (Slc21a1)- and Oatp2 (Slc21a5)-Mediated Transport , 2002, Pharmaceutical Research.

[94]  J. Donovan,et al.  Olanzapine Penetration into Brain is Greater in Transgenic Abcb1a P-glycoprotein-Deficient Mice than FVB1 (Wild-Type) Animals , 2004, Neuropsychopharmacology.

[95]  David S. Broomhead,et al.  Sensitivity analysis of parameters controlling oscillatory signalling in the NF-/sub K/Bpathway: the roles of IKK and I/sub K/B/sub alpha/ , 2004 .

[96]  Kwang-Jin Kim,et al.  Role of P-Glycoprotein in Restricting Propranolol Transport in Cultured Rabbit Conjunctival Epithelial Cell Layers , 2000, Pharmaceutical Research.

[97]  Ismael Zamora,et al.  pH-Dependent Bidirectional Transport of Weakly Basic Drugs Across Caco-2 Monolayers: Implications for Drug–Drug Interactions , 2003, Pharmaceutical Research.

[98]  M. Okuda,et al.  Different transport properties between famotidine and cimetidine by human renal organic ion transporters (SLC22A). , 2004, European journal of pharmacology.

[99]  R. Brereton,et al.  Handbook of chemoinformatics: from data to knowledge, edited by Johann Gasteiger, Volumes 1–4. Wiley‐VCH, Weinheim, 2003, ISBN 3527306803, €485 , 2004 .

[100]  Kiaran Kirk,et al.  The malaria parasite's chloroquine resistance transporter is a member of the drug/metabolite transporter superfamily. , 2004, Molecular biology and evolution.

[101]  Maristela Lika Onozato,et al.  Interactions of Human Organic Anion Transporters with Diuretics , 2004, Journal of Pharmacology and Experimental Therapeutics.

[102]  D. Broomhead,et al.  Sensitivity analysis of parameters controlling oscillatory signalling in the NFk B pathway : the roles of IKK and I k B a , 2004 .

[103]  M. Lazdunski,et al.  TREK‐1, a K+ channel involved in neuroprotection and general anesthesia , 2004, The EMBO journal.

[104]  I. Kola,et al.  Can the pharmaceutical industry reduce attrition rates? , 2004, Nature Reviews Drug Discovery.

[105]  B. Antkowiak,et al.  Molecular and systemic mechanisms of general anaesthesia: the ‘multi-site and multiple mechanisms’ concept , 2005, Current opinion in anaesthesiology.

[106]  R. Harris,et al.  Sites of alcohol and volatile anesthetic action on glycine receptors. , 2005, International review of neurobiology.

[107]  A S Verkman,et al.  Aquaporin‐3 functions as a glycerol transporter in mammalian skin , 2005, Biology of the cell.

[108]  Wolfgang Löscher,et al.  Role of drug efflux transporters in the brain for drug disposition and treatment of brain diseases , 2005, Progress in Neurobiology.

[109]  Dan S. Tawfik,et al.  The 'evolvability' of promiscuous protein functions , 2005, Nature Genetics.

[110]  Tudor I. Oprea,et al.  Chemoinformatics in drug discovery , 2005 .

[111]  H. Kusuhara,et al.  FUNCTIONAL INVOLVEMENT OF RAT ORGANIC ANION TRANSPORTER 2 (SLC22A7) IN THE HEPATIC UPTAKE OF THE NONSTEROIDAL ANTI-INFLAMMATORY DRUG KETOPROFEN , 2005, Drug Metabolism and Disposition.

[112]  Alfred H. Schinkel,et al.  Human Breast Cancer Resistance Protein: Interactions with Steroid Drugs, Hormones, the Dietary Carcinogen 2-Amino-1-methyl-6-phenylimidazo(4,5-b)pyridine, and Transport of Cimetidine , 2005, Journal of Pharmacology and Experimental Therapeutics.

[113]  J. Greef,et al.  Rescuing drug discovery: in vivo systems pathology and systems pharmacology , 2005, Nature Reviews Drug Discovery.

[114]  S. Bagnasco.  Role and regulation of urea transporters , 2005, Pflügers Archiv.

[115]  Simon K. Mencher,et al.  Promiscuous drugs compared to selective drugs (promiscuity can be a virtue) , 2005, BMC clinical pharmacology.

[116]  C. Orengo,et al.  Protein families and their evolution-a structural perspective. , 2005, Annual review of biochemistry.

[117]  Y. Sai,et al.  Biochemical and molecular pharmacological aspects of transporters as determinants of drug disposition. , 2005, Drug metabolism and pharmacokinetics.

[118]  A. Fliri,et al.  Analysis of drug-induced effect patterns to link structure and side effects of medicines , 2005, Nature chemical biology.

[119]  Mariël Brok,et al.  Chronic imatinib mesylate exposure leads to reduced intracellular drug accumulation by induction of the ABCG2 (BCRP) and ABCB1 (MDR1) drug transport pumps , 2005, Cancer biology & therapy.

[120]  J. Ioannidis.  Why Most Published Research Findings Are False , 2005, PLoS medicine.

[121]  Michael C Sanguinetti,et al.  Predicting drug-hERG channel interactions that cause acquired long QT syndrome. , 2005, Trends in pharmacological sciences.

[122]  H. Koepsell,et al.  Polyspecific cation transporters mediate luminal release of acetylcholine from bronchial epithelium. , 2005, American journal of respiratory cell and molecular biology.

[123]  K. Poole.  Efflux-mediated antimicrobial resistance. , 2005, The Journal of antimicrobial chemotherapy.

[124]  H. D. de Koning,et al.  Purine and pyrimidine transport in pathogenic protozoa: from biology to therapy. , 2005, FEMS microbiology reviews.

[125]  H. Schweizer,et al.  Bacterial resistance to antibiotics: active efflux and reduced uptake. , 2005, Advanced drug delivery reviews.

[126]  Douglas B. Kell,et al.  The role of modeling in systems biology , 2005 .

[127]  H. Ishiguro,et al.  Mechanisms of bicarbonate secretion in the pancreatic duct. , 2005, Annual review of physiology.

[128]  Dan S. Tawfik,et al.  Enzyme promiscuity: evolutionary and mechanistic aspects. , 2006, Current opinion in chemical biology.

[129]  Douglas B Kell,et al.  Theodor Bücher Lecture. Metabolomics, modelling and machine learning in systems biology - towards an understanding of the languages of cells. Delivered on 3 July 2005 at the 30th FEBS Congress and the 9th IUBMB conference in Budapest. , 2006, The FEBS journal.

[130]  D. Putt,et al.  Membrane transport function in primary cultures of human proximal tubular cells. , 2006, Toxicology.

[131]  V. Alibu,et al.  The role of Trypanosoma brucei MRPA in melarsoprol susceptibility. , 2006, Molecular and biochemical parasitology.

[132]  Serena M. Bagnasco,et al.  The Erythrocyte Urea Transporter UT-B , 2006, The Journal of Membrane Biology.

[133]  John P. Overington,et al.  Can we rationally design promiscuous drugs? , 2006, Current opinion in structural biology.

[134]  W. Boron,et al.  Evidence that aquaporin 1 is a major pathway for CO2 transport across the human erythrocyte membrane , 2006, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[135]  N. Franks,et al.  Molecular targets underlying general anaesthesia , 2006, British journal of pharmacology.

[136]  Sean Ekins,et al.  Pharmacophore-based discovery of ligands for drug transporters. , 2006, Advanced drug delivery reviews.

[137]  Y. Sawada,et al.  Inhibitory effects of angiotensin II receptor antagonists and leukotriene receptor antagonists on the transport of human organic anion transporter 4 , 2006, The Journal of pharmacy and pharmacology.

[138]  Dimitris K Agrafiotis,et al.  A QSAR Model of hERG Binding Using a Large, Diverse, and Internally Consistent Training Set , 2006, Chemical biology & drug design.

[139]  G. V. Paolini,et al.  Global mapping of pharmacological space , 2006, Nature Biotechnology.

[140]  D. Kell.  Systems biology, metabolic modelling and metabolomics in drug discovery and development. , 2006, Drug discovery today.

[141]  S. Croft,et al.  Mechanisms of experimental resistance of Leishmania to miltefosine: Implications for clinical use. , 2006, Drug resistance updates : reviews and commentaries in antimicrobial and anticancer chemotherapy.

[142]  B. Antkowiak,et al.  Anaesthetic drugs: linking molecular actions to clinical effects. , 2006, Current pharmaceutical design.

[143]  Christopher J Endres,et al.  The role of transporters in drug interactions. , 2006, European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences.

[144]  Michael J Sutcliffe,et al.  Molecular mechanisms for drug interactions with hERG that cause long QT syndrome , 2006, Expert opinion on drug metabolism & toxicology.

[145]  W. Pardridge.  Molecular Trojan horses for blood-brain barrier drug delivery. , 2006, Discovery medicine.

[146]  P. Imming,et al.  Drugs, their targets and the nature and number of drug targets , 2006, Nature Reviews Drug Discovery.

[147]  A. Kastrati,et al.  Impact of P‐glycoprotein on clopidogrel absorption , 2006, Clinical pharmacology and therapeutics.

[148]  R. Kim,et al.  Drug and bile acid transporters in rosuvastatin hepatic uptake: function, expression, and pharmacogenetics. , 2006, Gastroenterology.

[149]  Kathleen Barnes,et al.  Influence of leukotriene pathway polymorphisms on response to montelukast in asthma. , 2006, American journal of respiratory and critical care medicine.

[150]  J. Donovan,et al.  Evaluation of antipsychotic drugs as inhibitors of multidrug resistance transporter P-glycoprotein , 2006, Psychopharmacology.

[151]  G. Burckhardt,et al.  Organic Anion Transporters of the SLC22 Family: Biopharmaceutical, Physiological, and Pathological Roles , 2007, Pharmaceutical Research.

[152]  Praveen M. Bahadduri,et al.  Rapid Identification of P-glycoprotein Substrates and Inhibitors , 2006, Drug Metabolism and Disposition.

[153]  V. Vallon,et al.  Decreased Renal Organic Anion Secretion and Plasma Accumulation of Endogenous Organic Anions in OAT1 Knock-out Mice* , 2006, Journal of Biological Chemistry.

[154]  K. Maeda,et al.  Effects of organic anion transporting polypeptide 1B1 haplotype on pharmacokinetics of pravastatin, valsartan, and temocapril , 2006, Clinical pharmacology and therapeutics.

[155]  R. Alberty,et al.  Relations between biochemical thermodynamics and biochemical kinetics. , 2006, Biophysical chemistry.

[156]  Douglas B. Kell,et al.  Statistical strategies for avoiding false discoveries in metabolomics and related experiments , 2007, Metabolomics.

[157]  Nathan Brown,et al.  A Chemoinformatics Analysis of Hit Lists Obtained from High-Throughput Affinity-Selection Screening , 2006, Journal of biomolecular screening.

[158]  G. Sachs,et al.  Review article: the clinical pharmacology of proton pump inhibitors , 2006, Alimentary pharmacology & therapeutics.

[159]  K. Maeda,et al.  INVOLVEMENT OF TRANSPORTERS IN THE HEPATIC UPTAKE AND BILIARY EXCRETION OF VALSARTAN, A SELECTIVE ANTAGONIST OF THE ANGIOTENSIN II AT1-RECEPTOR, IN HUMANS , 2006, Drug Metabolism and Disposition.

[160]  B. Palsson.  Systems Biology: Properties of Reconstructed Networks , 2006 .

[161]  Katsuhisa Inoue,et al.  Glycerol uptake in HCT-15 human colon cancer cell line by Na(+)-dependent carrier-mediated transport. , 2006, Biological & pharmaceutical bulletin.

[162]  J. Keelan,et al.  Active transport across the human placenta: impact on drug efficacy and toxicity , 2006, Expert opinion on drug metabolism & toxicology.

[163]  Xiaomin Luo,et al.  TarFisDock: a web server for identifying drug targets with docking approach , 2006, Nucleic Acids Res..

[164]  D. Kell.  Metabolomics, modelling and machine learning in systems biology – towards an understanding of the languages of cells , 2006, The FEBS journal.

[165]  Christine Williams,et al.  Early evaluation of compound QT prolongation effects: a predictive 384-well fluorescence polarization binding assay for measuring hERG blockade. , 2007, Journal of pharmacological and toxicological methods.

[166]  M. Totrov,et al.  Waltzing transporters and 'the dance macabre' between humans and bacteria , 2007, Nature Reviews Drug Discovery.

[167]  J. Lima.  Treatment heterogeneity in asthma: genetics of response to leukotriene modifiers. , 2007, Molecular diagnosis & therapy.

[168]  Osamu Ogawa,et al.  Substrate specificity of MATE1 and MATE2-K, human multidrug and toxin extrusions/H(+)-organic cation antiporters. , 2007, Biochemical pharmacology.

[169]  P. Hardenbol,et al.  Comprehensive assessment of metabolic enzyme and transporter genes using the Affymetrix Targeted Genotyping System. , 2007, Pharmacogenomics.

[170]  R. Krauss,et al.  When good drugs go bad , 2007, Nature.

[171]  Xin Wen,et al.  BindingDB: a web-accessible database of experimentally determined protein–ligand binding affinities , 2006, Nucleic Acids Res..

[172]  A. Wanner,et al.  The effect of corticosteroids on the disposal of long-acting beta2-agonists by airway smooth muscle cells. , 2007, The Journal of allergy and clinical immunology.

[173]  V. Bellofatto.  Pyrimidine transport activities in trypanosomes. , 2007, Trends in parasitology.

[174]  P. Jeffrey,et al.  Challenges for blood–brain barrier (BBB) screening , 2007, Xenobiotica; the fate of foreign compounds in biological systems.

[175]  C. Xia,et al.  Evaluation of drug-transporter interactions using in vitro and in vivo models. , 2007, Current drug metabolism.

[176]  E. Bertaccini,et al.  The Common Chemical Motifs Within Anesthetic Binding Sites , 2007, Anesthesia and analgesia.

[177]  T. Terasaki,et al.  Contribution of Carrier-Mediated Transport Systems to the Blood–Brain Barrier as a Supporting and Protecting Interface for the Brain; Importance for CNS Drug Discovery and Development , 2007, Pharmaceutical Research.

[178]  M. Waring,et al.  A quantitative assessment of hERG liability as a function of lipophilicity. , 2007, Bioorganic & medicinal chemistry letters.

[179]  P. Leeson,et al.  The influence of drug-like concepts on decision-making in medicinal chemistry , 2007, Nature Reviews Drug Discovery.

[180]  A. Barabasi,et al.  Drug—target network , 2007, Nature Biotechnology.

[181]  Per Artursson,et al.  Expression of Thirty-six Drug Transporter Genes in Human Intestine, Liver, Kidney, and Organotypic Cell Lines , 2007, Drug Metabolism and Disposition.

[182]  P. Prasad,et al.  Molecular mechanism involved in the transport of a prodrug dopamine glycosyl conjugate. , 2007, International journal of pharmaceutics.

[183]  D. Labuda,et al.  Subcellular proteomics of cell differentiation: Quantitative analysis of the plasma membrane proteome of Caco‐2 cells , 2007, Proteomics.

[184]  O. Demin,et al.  The Edinburgh human metabolic network reconstruction and its functional analysis , 2007, Molecular systems biology.

[185]  P. Clemons,et al.  Chemogenomic data analysis: prediction of small-molecule targets and the advent of biological fingerprint. , 2007, Combinatorial chemistry & high throughput screening.

[186]  S. Meshnick,et al.  The Mitochondrion Is a Site of Trypanocidal Action of the Aromatic Diamidine DB75 in Bloodstream Forms of Trypanosoma brucei , 2007, Antimicrobial Agents and Chemotherapy.

[187]  Xiaomin Luo,et al.  PDTD: a web-accessible protein database for drug target identification , 2008, BMC Bioinformatics.

[188]  Douglas B Kell,et al.  The virtual human: Towards a global systems biology of multiscale, distributed biochemical network models , 2007, IUBMB life.

[189]  L. Hamm,et al.  Molecular mechanisms of renal ammonia transport. , 2007, Annual review of physiology.

[190]  Monica L. Mo,et al.  Global reconstruction of the human metabolic network based on genomic and bibliomic data , 2007, Proceedings of the National Academy of Sciences.

[191]  A. Bender,et al.  Modeling Promiscuity Based on in vitro Safety Pharmacology Profiling Data , 2007, ChemMedChem.

[192]  S. Lowes,et al.  The Contribution of Organic Anion Transporters OAT1 and OAT3 to the Renal Uptake of Rosuvastatin , 2007, Journal of Pharmacology and Experimental Therapeutics.

[193]  D. Broomhead,et al.  Something from nothing − bridging the gap between constraint‐based and kinetic modelling , 2007, The FEBS journal.

[194]  W. Pardridge,et al.  Blood-brain barrier delivery. , 2007, Drug discovery today.

[195]  Richard Morphy,et al.  Fragments, network biology and designing multiple ligands. , 2007, Drug discovery today.

[196]  F. Russel,et al.  Interaction of Nonsteroidal Anti-Inflammatory Drugs with Multidrug Resistance Protein (MRP) 2/ABCC2- and MRP4/ABCC4-Mediated Methotrexate Transport , 2007, Journal of Pharmacology and Experimental Therapeutics.

[197]  Michael J. Keiser,et al.  Relating protein pharmacology by ligand chemistry , 2007, Nature Biotechnology.

[198]  A. Bender,et al.  Analysis of Pharmacology Data and the Prediction of Adverse Drug Reactions and Off‐Target Effects from Chemical Structure , 2007, ChemMedChem.

[199]  Amin Rostami-Hodjegan,et al.  Simulation and prediction of in vivo drug metabolism in human populations from in vitro data , 2007, Nature Reviews Drug Discovery.

[200]  M. Leboyer,et al.  Pharmacogenetic study of atypical antipsychotic drug response: Involvement of the norepinephrine transporter gene , 2008, American journal of medical genetics. Part B, Neuropsychiatric genetics : the official publication of the International Society of Psychiatric Genetics.

[201]  T. Iwatsubo,et al.  Effect of cationic drugs on the transporting activity of human and rat OCT/Oct 1-3 in vitro and implications for drug-drug interactions. , 2008, Xenobiotica; the fate of foreign compounds in biological systems.

[202]  J. Leppänen,et al.  Large neutral amino acid transporter enables brain drug delivery via prodrugs. , 2008, Journal of medicinal chemistry.

[203]  Robert B. Russell,et al.  SuperTarget and Matador: resources for exploring drug-target relationships , 2007, Nucleic Acids Res..

[204]  J. Nutt,et al.  Strategies to advance translational research into brain barriers , 2008, The Lancet Neurology.

[205]  N. Franks.  General anaesthesia: from molecular targets to neuronal pathways of sleep and arousal , 2008, Nature Reviews Neuroscience.

[206]  Hong-Bin Chen,et al.  Development of a New Predictive Model for Interactions with Human Cytochrome P450 2A6 Using Pharmacophore Ensemble/Support Vector Machine (PhE/SVM) Approach , 2009, Pharmaceutical Research.

[207]  Douglas B Kell,et al.  Proximate parameter tuning for biochemical networks with uncertain kinetic parameters. , 2008, Molecular bioSystems.

[208]  A. Małecki,et al.  Physiology and pharmacological role of the blood-brain barrier. , 2008, Pharmacological reports : PR.

[209]  S. Baker,et al.  Interaction of Imatinib with Human Organic Ion Carriers , 2008, Clinical Cancer Research.

[210]  A. Cavalli,et al.  Modeling hERG and its Interactions with Drugs: Recent Advances in Light of Current Potassium Channel Simulations , 2008, ChemMedChem.

[211]  F. Russel,et al.  Mechanisms of renal anionic drug transport. , 2008, European journal of pharmacology.

[212]  J A Peters,et al.  Guide to Receptors and Channels (GRAC), 3rd edition , 2008, British journal of pharmacology.

[213]  Antony J. Williams,et al.  A perspective of publicly accessible/open-access chemistry databases. , 2008, Drug discovery today.

[214]  V. Vallon,et al.  Overlapping in vitro and in vivo specificities of the organic anion transporters OAT1 and OAT3 for loop and thiazide diuretics. , 2008, American journal of physiology. Renal physiology.

[215]  Markus J. Herrgård,et al.  A consensus yeast metabolic network reconstruction obtained from a community approach to systems biology , 2008, Nature Biotechnology.

[216]  W. Geldenhuys,et al.  Carrier-Mediated Transport of the Quaternary Ammonium Neuronal Nicotinic Receptor Antagonist N,N′-Dodecylbispicolinium Dibromide at the Blood-Brain Barrier , 2008, Journal of Pharmacology and Experimental Therapeutics.

[217]  B. Priest,et al.  Role of hERG potassium channel assays in drug development , 2008, Channels.

[218]  Alan Stobie,et al.  Pyridyl-phenyl ether monoamine reuptake inhibitors: Impact of lipophilicity on dual SNRI pharmacology and off-target promiscuity. , 2008, Bioorganic & medicinal chemistry letters.

[219]  Mark A. Girolami,et al.  Bayesian ranking of biochemical system models , 2008, Bioinform..

[220]  D. Kell,et al.  Carrier-mediated cellular uptake of pharmaceutical drugs: an exception or the rule? , 2008, Nature Reviews Drug Discovery.

[221]  Antony J Williams,et al.  Internet-based tools for communication and collaboration in chemistry. , 2008, Drug discovery today.

[222]  Markus J. Herrgård,et al.  Network-based prediction of human tissue-specific metabolism , 2008, Nature Biotechnology.

[223]  Christophe Maurel,et al.  Plant aquaporins: membrane channels with multiple integrated functions. , 2008, Annual review of plant biology.

[224]  Christel A. S. Bergström,et al.  Structural requirements for drug inhibition of the liver specific human organic cation transport protein 1. , 2008, Journal of medicinal chemistry.

[225]  MB Kelz,et al.  From Anesthetic Mechanisms Research to Drug Discovery , 2008, Clinical pharmacology and therapeutics.

[226]  A. Hopkins.  Network pharmacology: the next paradigm in drug discovery. , 2008, Nature chemical biology.

[227]  Magnus Rattray,et al.  Bayesian inference of the sites of perturbations in metabolic pathways via Markov chain Monte Carlo , 2008, Bioinform..

[228]  I. Kola,et al.  The State of Innovation in Drug Development , 2008, Clinical pharmacology and therapeutics.

[229]  Fei He,et al.  Sensitivity analysis and robust experimental design of a signal transduction pathway system , 2008 .

[230]  Ever-increasing complexities of diamidine and arsenical crossresistance in African trypanosomes. , 2008, Trends in parasitology.

[231]  Pascale Anderle,et al.  Transporter and ion channel gene expression after caco-2 cell differentiation using 2 different microarray technologies , 2004, The AAPS Journal.

[232]  D. Hoyle,et al.  Identification and characterization of high-flux-control genes of yeast through competition analyses in continuous cultures , 2008, Nature Genetics.

[233]  M. Roberts,et al.  Update on macrolide-lincosamide-streptogramin, ketolide, and oxazolidinone resistance genes. , 2008, FEMS microbiology letters.

[234]  Matteo Masetti,et al.  Modeling hERG and its Interactions with Drugs: Recent Advances in Light of Current Potassium Channel Simulations , 2008, ChemMedChem.

[235]  D. Kell.  Iron behaving badly: inappropriate iron chelation as a major contributor to the aetiology of vascular and other progressive inflammatory and degenerative diseases , 2008, BMC Medical Genomics.

[236]  J. Mestres,et al.  A ligand-based approach to mining the chemogenomic space of drugs. , 2008, Combinatorial chemistry & high throughput screening.

[237]  K. Inui,et al.  Physiological and pharmacokinetic roles of H+/organic cation antiporters (MATE/SLC47A). , 2008, Biochemical pharmacology.

[238]  B. Orser,et al.  GABAA receptor subtypes underlying general anesthesia , 2008, Pharmacology Biochemistry and Behavior.

[239]  Mark A. Girolami,et al.  Bayesian ranking of biochemical system models , 2008, Bioinform..

[240]  P. Artursson,et al.  Comparison of drug transporter gene expression and functionality in Caco-2 cells from 10 different laboratories. , 2008, European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences.

[241]  A. Y. Lu,et al.  The challenges of dealing with promiscuous drug-metabolizing enzymes, receptors and transporters. , 2008, Current drug metabolism.

[242]  H. Schiöth,et al.  The solute carrier (SLC) complement of the human genome: Phylogenetic classification reveals four major families , 2008, FEBS letters.

[243]  Steve Pettifer,et al.  Defrosting the Digital Library: Bibliographic Tools for the Next Generation Web , 2008, PLoS Comput. Biol..

[244]  P. Bork,et al.  Drug Target Identification Using Side-Effect Similarity , 2008, Science.

[245]  E. Poluzzi,et al.  The hERG K+ channel: target and antitarget strategies in drug development. , 2008, Pharmacological research.

[246]  Jamie I Vandenberg,et al.  Human ether-a-go-go related gene (hERG) K+ channels: function and dysfunction. , 2008, Progress in biophysics and molecular biology.

[247]  Janet M. Thornton,et al.  PROCOGNATE: a cognate ligand domain mapping for enzymes , 2007, Nucleic Acids Res..

[248]  Saltelli Andrea,et al.  Global Sensitivity Analysis: The Primer , 2008 .

[249]  J. Weinstein,et al.  Profiling SLCO and SLC22 genes in the NCI-60 cancer cell lines to identify drug uptake transporters , 2008, Molecular Cancer Therapeutics.

[250]  Mikko Gynther,et al.  Prodrug Approaches for CNS Delivery , 2008, The AAPS Journal.

[251]  A. Dalpiaz,et al.  Progress in Drug Delivery to the Central Nervous System by the Prodrug Approach , 2008, Molecules.

[252]  Katsuhisa Inoue,et al.  Functional characterization of human aquaporin 9 as a facilitative glycerol carrier. , 2008, Drug metabolism and pharmacokinetics.

[253]  H. McLeod,et al.  Clopidogrel pharmacogenomics and risk of inadequate platelet inhibition: US FDA recommendations. , 2009, Pharmacogenomics.

[254]  R. Koch,et al.  ABC transporter A3 facilitates lysosomal sequestration of imatinib and modulates susceptibility of chronic myeloid leukemia cell lines to this drug , 2009, Haematologica.

[255]  Bin Chen,et al.  Gaining Insight into Off-Target Mediated Effects of Drug Candidates with a Comprehensive Systems Chemical Biology Analysis , 2009, J. Chem. Inf. Model..

[256]  R. Kim,et al.  Blood−brain barrier transporters and response to CNS-active drugs , 2009, European Journal of Clinical Pharmacology.

[257]  C. Saccar.  The pharmacology of esomeprazole and its role in gastric acid related diseases , 2009, Expert opinion on drug metabolism & toxicology.

[258]  H. Daniel,et al.  High-Affinity Interaction of Sartans with H+/Peptide Transporters , 2009, Drug Metabolism and Disposition.

[259]  L. Daws.  Unfaithful neurotransmitter transporters: focus on serotonin uptake and implications for antidepressant efficacy. , 2009, Pharmacology & therapeutics.

[260]  M. Niemi,et al.  Impact of OATP transporters on pharmacokinetics , 2009, British journal of pharmacology.

[261]  Kirsi Vähäkangas,et al.  Drug transporters in the human blood‐placental barrier , 2009, British journal of pharmacology.

[262]  R. Solé,et al.  The topology of drug-target interaction networks: implicit dependence on drug properties and target families. , 2009, Molecular bioSystems.

[263]  L. Varatharajan,et al.  The transport of anti-HIV drugs across blood–CNS interfaces: Summary of current knowledge and recommendations for further research , 2009, Antiviral research.

[264]  J. Mestres,et al.  Conciliating binding efficiency and polypharmacology. , 2009, Trends in pharmacological sciences.

[265]  Ruedi Aebersold,et al.  Analysis of Cell Surface Proteome Changes via Label-free, Quantitative Mass Spectrometry*S , 2009, Molecular & Cellular Proteomics.

[266]  Y. Sugiyama,et al.  Genetic polymorphisms of uptake (OATP1B1, 1B3) and efflux (MRP2, BCRP) transporters: implications for inter-individual differences in the pharmacokinetics and pharmacodynamics of statins and other clinically relevant drugs , 2009, Expert opinion on drug metabolism & toxicology.

[267]  Y. Kato,et al.  Involvement of influx and efflux transport systems in gastrointestinal absorption of celiprolol. , 2009, Journal of pharmaceutical sciences.

[268]  M. Pirmohamed,et al.  Adverse Drug Reactions in Hospital In-Patients: A Prospective Analysis of 3695 Patient-Episodes , 2009, PloS one.

[269]  Michael J. Keiser,et al.  Off-target networks derived from ligand set similarity. , 2009, Methods in molecular biology.

[270]  P. Neuvonen,et al.  ABCG2 Polymorphism Markedly Affects the Pharmacokinetics of Atorvastatin and Rosuvastatin , 2009, Clinical pharmacology and therapeutics.

[271]  J. Peters,et al.  Pharmacological Promiscuity: Dependence on Compound Properties and Target Specificity in a Set of Recent Roche Compounds , 2009, ChemMedChem.

[272]  Andrew L. Hopkins,et al.  Predicting promiscuity , 2009 .

[273]  L. Bunch,et al.  Excitatory amino acid transporters as potential drug targets , 2009, Expert opinion on therapeutic targets.

[274]  D. Kell,et al.  'Metabolite-likeness' as a criterion in the design and selection of pharmaceutical drug libraries. , 2009, Drug discovery today.

[275]  C. Gattass,et al.  Topological polar surface area defines substrate transport by multidrug resistance associated protein 1 (MRP1/ABCC1). , 2009, Journal of medicinal chemistry.

[276]  Andrew L. Hopkins,et al.  Drug discovery: Predicting promiscuity , 2009, Nature.

[277]  D. Rees,et al.  ABC transporters: the power to change , 2009, Nature Reviews Molecular Cell Biology.

[278]  Kairui Feng,et al.  The Simcyp® Population-based ADME Simulator , 2009 .

[279]  Maurizio Recanatini,et al.  hERG-related drug toxicity and models for predicting hERG liability and QT prolongation , 2009, Expert opinion on drug metabolism & toxicology.

[280]  S. Masuda,et al.  Protective effect of concomitant administration of imatinib on cisplatin-induced nephrotoxicity focusing on renal organic cation transporter OCT2. , 2009, Biochemical pharmacology.

[281]  Leslie Z. Benet,et al.  The Role of Transporters in the Pharmacokinetics of Orally Administered Drugs , 2009, Pharmaceutical Research.

[282]  Douglas B Kell,et al.  Implications of the dominant role of transporters in drug uptake by cells. , 2009, Current topics in medicinal chemistry.

[283]  G. Chakravarty,et al.  Montelukast is a potent and durable inhibitor of multidrug resistance protein 2-mediated efflux of taxol and saquinavir. , 2009, Biological & pharmaceutical bulletin.

[284]  R. Gabathuler.  Blood-brain barrier transport of drugs for the treatment of brain diseases. , 2009, CNS & neurological disorders drug targets.

[285]  Kairui Feng,et al.  The Simcyp population-based ADME simulator. , 2009, Expert opinion on drug metabolism & toxicology.

[286]  Ravi Iyengar,et al.  Network analyses in systems pharmacology , 2009, Bioinform..

[287]  Angelo D. Favia,et al.  Protein promiscuity and its implications for biotechnology , 2009, Nature Biotechnology.

[288]  Gerhard F. Ecker,et al.  Similarity-based SIBAR descriptors for classification of chemically diverse hERG blockers , 2009, Molecular Diversity.

[289]  S. Alper.  Molecular physiology and genetics of Na+-independent SLC4 anion exchangers , 2009, Journal of Experimental Biology.

[290]  Thierry Lavé,et al.  Prediction of pharmacokinetic profile of valsartan in human based on in vitro uptake transport data , 2009, Journal of Pharmacokinetics and Pharmacodynamics.

[291]  Ravi Iyengar,et al.  Systems pharmacology and genome medicine: a future perspective , 2009, Genome Medicine.

[292]  Lin He,et al.  SePreSA: a server for the prediction of populations susceptible to serious adverse drug reactions implementing the methodology of a chemical–protein interactome , 2009, Nucleic Acids Res..

[293]  M. Milik,et al.  Mapping adverse drug reactions in chemical space. , 2009, Journal of medicinal chemistry.

[294]  Y. Karamanos,et al.  Understanding the blood–brain barrier using gene and protein expression profiling technologies , 2009, Brain Research Reviews.

[295]  Sara Eyal,et al.  Drug interactions at the blood-brain barrier: fact or fantasy? , 2009, Pharmacology & therapeutics.

[296]  Yue Weng,et al.  Structure of P-Glycoprotein Reveals a Molecular Basis for Poly-Specific Drug Binding , 2009, Science.

[297]  M. Jamei,et al.  A framework for assessing inter-individual variability in pharmacokinetics using virtual human populations and integrating general knowledge of physical chemistry, biology, anatomy, physiology and genetics: A tale of 'bottom-up' vs 'top-down' recognition of covariates. , 2009, Drug metabolism and pharmacokinetics.

[298]  P. Wellendorph,et al.  Molecular Pharmacology of Promiscuous Seven Transmembrane Receptors Sensing Organic Nutrients , 2009, Molecular Pharmacology.

[299]  M. Fromm,et al.  Functional Characterization of the Human Organic Cation Transporter 2 Variant p.270Ala>Ser , 2009, Drug Metabolism and Disposition.

[300]  J. Lima,et al.  Absorption of montelukast is transporter mediated: a common variant of OATP2B1 is associated with reduced plasma concentrations and poor response , 2009, Pharmacogenetics and genomics.

[301]  D. Kell,et al.  The cellular uptake of pharmaceutical drugs is mainly carrier-mediated and is thus an issue not so much of biophysics but of systems biology , 2009 .

[302]  J. Leppänen,et al.  Glucose promoiety enables glucose transporter mediated brain uptake of ketoprofen and indomethacin prodrugs in rats. , 2009, Journal of medicinal chemistry.

[303]  Charles Elkan,et al.  The Transporter Classification Database: recent advances , 2008, Nucleic Acids Res..

[304]  Marisa Wong Medina,et al.  Pharmacogenomic Discovery Using Cell-Based Models , 2009, Pharmacological Reviews.

[305]  D. Kell,et al.  Calling International Rescue: knowledge lost in literature and data landslide! , 2009, The Biochemical journal.

[306]  Keunwan Park,et al.  Predicting the multi-modal binding propensity of small molecules: towards an understanding of drug promiscuity. , 2009, Molecular bioSystems.

[307]  Albert J R Heck,et al.  Revealing promiscuous drug-target interactions by chemical proteomics. , 2009, Drug discovery today.

[308]  M. Morris,et al.  The Drug of Abuse γ-Hydroxybutyrate Is a Substrate for Sodium-Coupled Monocarboxylate Transporter (SMCT) 1 (SLC5A8): Characterization of SMCT-Mediated Uptake and Inhibition , 2009, Drug Metabolism and Disposition.

[309]  Nigel Greene,et al.  Physicochemical drug properties associated with in vivo toxicological outcomes: a review , 2009, Expert opinion on drug metabolism & toxicology.

[310]  M. Uhlén,et al.  Endogenous Gene and Protein Expression of Drug-Transporting Proteins in Cell Lines Routinely Used in Drug Discovery Programs , 2009, Drug Metabolism and Disposition.

[311]  K. Brooks,et al.  Multiple Genetic Mechanisms Lead to Loss of Functional TbAT1 Expression in Drug-Resistant Trypanosomes , 2009, Eukaryotic Cell.

[312]  Sarath Chandra Janga,et al.  Structure and organization of drug-target networks: insights from genomic approaches for drug discovery. , 2009, Molecular bioSystems.

[313]  Michael J. Keiser,et al.  Predicting new molecular targets for known drugs , 2009, Nature.

[314]  S. Landfear,et al.  Two novel nucleobase/pentamidine transporters from Trypanosoma brucei. , 2009, Molecular and biochemical parasitology.

[315]  Russ B. Altman,et al.  Pharmacogenomics and bioinformatics: PharmGKB. , 2010, Pharmacogenomics.

[316]  M. Varma,et al.  Targeting intestinal transporters for optimizing oral drug absorption. , 2010, Current drug metabolism.

[317]  Azeem Majeed,et al.  Ten-year trends in hospital admissions for adverse drug reactions in England 1999–2009 , 2010, Journal of the Royal Society of Medicine.

[318]  Paul D. Leeson,et al.  Reducing the Risk of Drug Attrition Associated with Physicochemical Properties , 2010 .

[319]  Shiew-Mei Huang,et al.  Drug interactions evaluation: an integrated part of risk assessment of therapeutics. , 2010, Toxicology and applied pharmacology.

[320]  Alejandro Llanos-Cuentas,et al.  Whole-genome sequencing and microarray analysis of ex vivo Plasmodium vivax reveal selective pressure on putative drug resistance genes , 2010, Proceedings of the National Academy of Sciences.

[321]  B. Hagenbuch.  Drug Uptake Systems in Liver and Kidney: A Historic Perspective , 2010, Clinical pharmacology and therapeutics.

[322]  Dora Brites,et al.  Looking at the blood–brain barrier: Molecular anatomy and possible investigation approaches , 2010, Brain Research Reviews.

[323]  Y. Hagos,et al.  Assessment of the Role of Renal Organic Anion Transporters in Drug-Induced Nephrotoxicity , 2010, Toxins.

[324]  David N. LeBard,et al.  Multiple binding sites for the general anesthetic isoflurane identified in the nicotinic acetylcholine receptor transmembrane domain , 2010, Proceedings of the National Academy of Sciences.

[325]  E. Wiemer,et al.  Drug Transporters and Imatinib Treatment: Implications for Clinical Practice , 2010, Clinical Cancer Research.

[326]  M. Hohenegger,et al.  Double impact on p‐glycoprotein by statins enhances doxorubicin cytotoxicity in human neuroblastoma cells , 2009, International journal of cancer.

[327]  K M Giacomini,et al.  The International Transporter Consortium: A Collaborative Group of Scientists From Academia, Industry, and the FDA , 2010, Clinical pharmacology and therapeutics.

[328]  Bradley L Urquhart,et al.  Human Skeletal Muscle Drug Transporters Determine Local Exposure and Toxicity of Statins , 2010, Circulation research.

[329]  F. Russel,et al.  Therapeutic implications of renal anionic drug transporters. , 2010, Pharmacology & therapeutics.

[330]  R. Kim,et al.  Human multidrug and toxin extrusion 1 (MATE1/SLC47A1) transporter: functional characterization, interaction with OCT2 (SLC22A2), and single nucleotide polymorphisms. , 2010, American journal of physiology. Renal physiology.

[331]  S. Zeng,et al.  Stereoselective transport and uptake of propranolol across human intestinal Caco-2 cell monolayers. , 2009, Chirality.

[332]  R. Gabathuler,et al.  Approaches to transport therapeutic drugs across the blood–brain barrier to treat brain diseases , 2010, Neurobiology of Disease.

[333]  Hong-Jian Zhu,et al.  Proteomics Profiling of Madin-Darby Canine Kidney Plasma Membranes Reveals Wnt-5a Involvement during Oncogenic H-Ras/TGF-β-mediated Epithelial-Mesenchymal Transition* , 2010, Molecular & Cellular Proteomics.

[334]  Rowena E. Martin,et al.  Functional characteristics of the malaria parasite's "chloroquine resistance transporter": Implications for chemotherapy , 2010, Virulence.

[335]  D. Thwaites,et al.  Hijacking solute carriers for proton-coupled drug transport. , 2010, Physiology.

[336]  S. Muresan,et al.  Investigation of the relationship between topology and selectivity for druglike molecules. , 2010, Journal of medicinal chemistry.

[337]  A. Sali,et al.  Comparison of human solute carriers , 2010, Protein science : a publication of the Protein Society.

[338]  W. Geldenhuys,et al.  Predictive screening model for potential vector-mediated transport of cationic substrates at the blood-brain barrier choline transporter. , 2010, Bioorganic & medicinal chemistry letters.

[339]  Shiew-Mei Huang,et al.  Pharmacogenomics and adverse drug reactions. , 2010, Personalized medicine.

[340]  K. Maeda,et al.  The use of hepatocytes to investigate drug uptake transporters. , 2010, Methods in molecular biology.

[341]  P. Bork,et al.  A side effect resource to capture phenotypic effects of drugs , 2010, Molecular systems biology.

[342]  M. Niemi,et al.  Membrane transporters in drug development , 2010, Nature Reviews Drug Discovery.

[343]  Kevin Y. Yip,et al.  Extensive In Vivo Metabolite-Protein Interactions Revealed by Large-Scale Systematic Analyses , 2010, Cell.

[344]  R. Iyengar,et al.  Systems approaches to polypharmacology and drug discovery. , 2010, Current opinion in drug discovery & development.

[345]  C. Bosquillon,et al.  Drug transporters in the lung--do they play a role in the biopharmaceutics of inhaled drugs? , 2010, Journal of pharmaceutical sciences.

[346]  P. Hajduk,et al.  Rational approaches to targeted polypharmacology: creating and navigating protein-ligand interaction networks. , 2010, Current opinion in chemical biology.

[347]  W. Geldenhuys,et al.  Exploiting nutrient transporters at the blood-brain barrier to improve brain distribution of small molecules. , 2010, Therapeutic delivery.

[348]  Navdeep Jaitly,et al.  A Structure-Based Approach for Mapping Adverse Drug Reactions to the Perturbation of Underlying Biological Pathways , 2010, PloS one.

[349]  A. D. Rodrigues,et al.  Enzyme- and transporter-based drug-drug Interactions : progress and future challenges , 2010 .

[350]  B. Barres,et al.  The Mouse Blood-Brain Barrier Transcriptome: A New Resource for Understanding the Development and Function of Brain Endothelial Cells , 2010, PloS one.

[351]  Dan S. Tawfik,et al.  Enzyme promiscuity: a mechanistic and evolutionary perspective. , 2010, Annual review of biochemistry.

[352]  E. Boulpaep,et al.  Substrate specificity of Rhbg: ammonium and methyl ammonium transport. , 2010, American journal of physiology. Cell physiology.

[353]  Jürgen Bajorath,et al.  Polypharmacology Directed Compound Data Mining: Identification of Promiscuous Chemotypes with Different Activity Profiles and Comparison to Approved Drugs , 2010, J. Chem. Inf. Model..

[354]  J. Leppänen,et al.  Brain uptake of ketoprofen-lysine prodrug in rats. , 2010, International journal of pharmaceutics.

[355]  M. Niemi.  Transporter Pharmacogenetics and Statin Toxicity , 2010, Clinical pharmacology and therapeutics.

[356]  A Rostami-Hodjegan,et al.  Interplay of metabolism and transport in determining oral drug absorption and gut wall metabolism: a simulation assessment using the "Advanced Dissolution, Absorption, Metabolism (ADAM)" model. , 2010, Current drug metabolism.

[357]  B. Gerrits,et al.  Proteomic cell surface phenotyping of differentiating acute myeloid leukemia cells. , 2010, Blood.

[358]  David J. Begley,et al.  Structure and function of the blood–brain barrier , 2010, Neurobiology of Disease.

[359]  John P. Overington,et al.  Role of open chemical data in aiding drug discovery and design. , 2010, Future medicinal chemistry.

[360]  Shehab Mahmoud,et al.  Brain‐Specific Delivery of Naproxen Using Different Carrier Systems , 2010, Archiv der Pharmazie.

[361]  A. D. Rodrigues,et al.  Enzyme- and transporter-based drug-drug Interaction , 2010 .

[362]  Andrew Jenkins,et al.  General Anesthetic Actions on GABAA Receptors , 2010, Current neuropharmacology.

[363]  Jordi Mestres,et al.  Anticipating drug side effects by comparative pharmacology , 2010, Expert opinion on drug metabolism & toxicology.

[364]  M. Waring.  Lipophilicity in drug discovery , 2010, Expert Opinion on Drug Discovery.

[365]  S. Bernèche,et al.  Transport mechanisms in the ammonium transporter family. , 2010, Transfusion clinique et biologique : journal de la Societe francaise de transfusion sanguine.

[366]  Leslie Z Benet,et al.  Predicting drug disposition via application of a Biopharmaceutics Drug Disposition Classification System. , 2010, Basic & clinical pharmacology & toxicology.

[367]  E. Lundberg,et al.  Creation of an antibody‐based subcellular protein atlas , 2010, Proteomics.

[368]  E. Bates,et al.  Genetic Causes of Clopidogrel Nonresponsiveness: Which Ones Really Count? , 2010, Pharmacotherapy.

[369]  Li Di,et al.  Coexistence of passive and carrier-mediated processes in drug transport , 2010, Nature Reviews Drug Discovery.

[370]  D. Venzon,et al.  Clinical pharmacology and pharmacogenetics in a genomics era: the DMET platform. , 2010, Pharmacogenomics.

[371]  Frans G. M. Russel,et al.  Transporters: Importance in Drug Absorption, Distribution, and Removal , 2010 .

[372]  David S. Wishart,et al.  T3DB: a comprehensively annotated database of common toxins and their targets , 2009, Nucleic Acids Res..

[373]  SRB Allerheiligen,et al.  Next‐Generation Model‐Based Drug Discovery and Development: Quantitative and Systems Pharmacology , 2010, Clinical pharmacology and therapeutics.

[374]  Yuichi Sugiyama,et al.  Application of physiologically based pharmacokinetic modeling and clearance concept to drugs showing transporter-mediated distribution and clearance in humans , 2010, Journal of Pharmacokinetics and Pharmacodynamics.

[375]  M. Fromm,et al.  Hepatic OATP and OCT uptake transporters: their role for drug-drug interactions and pharmacogenetic aspects , 2010, Drug metabolism reviews.

[376]  Ines Thiele,et al.  Reconstruction annotation jamborees: a community approach to systems biology , 2010, Molecular systems biology.

[377]  Tudor I. Oprea,et al.  iPHACE: integrative navigation in pharmacological space , 2010, Bioinform..

[378]  S. Bryant,et al.  PubChem as a public resource for drug discovery. , 2010, Drug discovery today.

[379]  Yoshihiro Yamanishi,et al.  Predicting drug side-effect profiles: a chemical fragment-based approach , 2011, BMC Bioinformatics.

[380]  Douglas B. Kell,et al.  Towards a unifying, systems biology understanding of large-scale cellular death and destruction caused by poorly liganded iron: Parkinson’s, Huntington’s, Alzheimer’s, prions, bactericides, chemical toxicology and others as examples , 2010, Archives of Toxicology.

[381]  R. Bendayan,et al.  The complexities of antiretroviral drug-drug interactions: role of ABC and SLC transporters. , 2010, Trends in pharmacological sciences.

[382]  T. Kusaka,et al.  Transporters in the brain endothelial barrier. , 2010, Current medicinal chemistry.

[383]  M. Sanguinetti,et al.  SYMPOSIUM REVIEW: Revealing the structural basis of action of hERG potassium channel activators and blockers , 2010, The Journal of physiology.

[384]  Christoph Steinbeck,et al.  Chemical Entities of Biological Interest: an update , 2009, Nucleic Acids Res..

[385]  Wandong Zhang,et al.  ABC Transporters and Drug Efflux at the Blood-Brain Barrier , 2010, Reviews in the neurosciences.

[386]  M. Gionfriddo,et al.  Organic anion transporters: discovery, pharmacology, regulation and roles in pathophysiology. , 2009, Biopharmaceutics & drug disposition.

[387]  Sean Ekins,et al.  Quantitative structure activity relationship for inhibition of human organic cation/carnitine transporter. , 2010, Molecular pharmaceutics.

[388]  Olga Khersonsky,et al.  8.03 – Enzyme Promiscuity – Evolutionary and Mechanistic Aspects , 2010 .

[389]  E. Lundberg,et al.  Towards a knowledge-based Human Protein Atlas , 2010, Nature Biotechnology.

[390]  P. Aloy,et al.  Unveiling the role of network and systems biology in drug discovery. , 2010, Trends in pharmacological sciences.

[391]  A. Rodrigues.  Efflux and uptake transporters as determinants of statin response , 2010, Expert opinion on drug metabolism & toxicology.

[392]  Michael J. Keiser,et al.  The Chemical Basis of Pharmacology , 2010, Biochemistry.

[393]  A. Avdeef,et al.  Physicochemical Selectivity of the BBB Microenvironment Governing Passive Diffusion—Matching with a Porcine Brain Lipid Extract Artificial Membrane Permeability Model , 2011, Pharmaceutical Research.

[394]  Pär Matsson,et al.  Profiling of a prescription drug library for potential renal drug-drug interactions mediated by the organic cation transporter 2. , 2011, Journal of medicinal chemistry.

[395]  M. Fromm,et al.  Transporter‐Mediated Drug Uptake and Efflux: Important Determinants of Adverse Drug Reactions , 2011, Clinical pharmacology and therapeutics.

[396]  R. Franke,et al.  Transcellular movement of hydroxyurea is mediated by specific solute carrier transporters. , 2011, Experimental hematology.

[397]  Avner Schlessinger,et al.  Structure-based discovery of prescription drugs that interact with the norepinephrine transporter, NET , 2011, Proceedings of the National Academy of Sciences.

[398]  Katsuhisa Inoue,et al.  Dual Functional Characteristic of Human Aquaporin 10 for Solute Transport , 2011, Cellular Physiology and Biochemistry.

[399]  T. Thompson.  The Clinical Significance of Drug Transporters in Drug Disposition and Drug Interactions , 2011 .

[400]  Jürgen Bajorath,et al.  Mapping of pharmacological space , 2011, Expert opinion on drug discovery.

[401]  Flemming Steen Jørgensen,et al.  In silico predictions of hERG channel blockers in drug discovery: from ligand-based and target-based approaches to systems chemical biology. , 2011, Combinatorial chemistry & high throughput screening.

[402]  Stephen P. H. Alexander,et al.  Guide to Receptors and Channels (GRAC), 5th edition , 2011, British journal of pharmacology.

[403]  R. Iyengar,et al.  Systems pharmacology of complex diseases , 2011, Annals of the New York Academy of Sciences.

[404]  D. Horn,et al.  Genome-wide RNAi screens in African trypanosomes identify the nifurtimox activator NTR and the eflornithine transporter AAT6 , 2011, Molecular and biochemical parasitology.

[405]  Tudor I. Oprea,et al.  BDDCS Applied to Over 900 Drugs , 2011, The AAPS Journal.

[406]  J. Verlander,et al.  Role of NH3 and NH4+ transporters in renal acid-base transport. , 2011, American journal of physiology. Renal physiology.

[407]  Li Hai,et al.  Design, synthesis and biological evaluation of brain-specific glucosyl thiamine disulfide prodrugs of naproxen. , 2011, European journal of medicinal chemistry.

[408]  Yoichi Kameda,et al.  Immunohistochemical Analysis of Human Equilibrative Nucleoside Transporter-1 (hENT1) Predicts Survival in Resected Pancreatic Cancer Patients Treated with Adjuvant Gemcitabine Monotherapy , 2012, Annals of Surgical Oncology.

[409]  Alfons Nonell-Canals,et al.  In Silico Target Profiling of One Billion Molecules , 2011, Molecular informatics.

[410]  J. Polli,et al.  Synthesis and in vitro characterization of drug conjugates of l-carnitine as potential prodrugs that target human Octn2. , 2011, Journal of pharmaceutical sciences.

[411]  T. Wellems,et al.  Malaria drug resistance: new observations and developments. , 2011, Essays in biochemistry.

[412]  F. Van Bambeke,et al.  ABC multidrug transporters: target for modulation of drug pharmacokinetics and drug-drug interactions. , 2011, Current drug targets.

[413]  G. Ciarimboli.  Role of organic cation transporters in drug-induced toxicity , 2011, Expert opinion on drug metabolism & toxicology.

[414]  A. Yonezawa,et al.  Importance of the multidrug and toxin extrusion MATE/SLC47A family to pharmacokinetics, pharmacodynamics/toxicodynamics and pharmacogenomics , 2011, British journal of pharmacology.

[415]  R. Tirona.  Molecular mechanisms of drug transporter regulation. , 2011, Handbook of experimental pharmacology.

[416]  Philip E. Bourne,et al.  PROMISCUOUS: a database for network-based drug-repositioning , 2010, Nucleic Acids Res..

[417]  H. Bayley,et al.  Fluorinated amphiphiles control the insertion of α-hemolysin pores into lipid bilayers. , 2011, Biochemistry.

[418]  J. Leppänen,et al.  Large amino acid transporter 1 (LAT1) prodrugs of valproic acid: new prodrug design ideas for central nervous system delivery. , 2011, Molecular pharmaceutics.

[419]  J. Kehr,et al.  Cytochrome P450 and ABCB1 genetics: association with quetiapine and norquetiapine plasma and cerebrospinal fluid concentrations and with clinical response in patients suffering from schizophrenia. A pilot study , 2011, Journal of psychopharmacology.

[420]  Overview of SLC22A and SLCO families of drug uptake transporters in the context of cancer treatments. , 2011, Current drug metabolism.

[421]  P. Dawson.  Role of the intestinal bile acid transporters in bile acid and drug disposition. , 2011, Handbook of experimental pharmacology.

[422]  A. R. Fernandes,et al.  Development of imatinib and dasatinib resistance: dynamics of expression of drug transporters ABCB1, ABCC1, ABCG2, MVP, and SLC22A1 , 2011, Leukemia & lymphoma.

[423]  T. Abe,et al.  Screening of antibiotics that interact with organic anion-transporting polypeptides 1B1 and 1B3 using fluorescent probes. , 2011, Biological & pharmaceutical bulletin.

[424]  Isabel M. Vincent,et al.  Drug resistance in human African trypanosomiasis. , 2011, Future microbiology.

[425]  P. Neuvonen,et al.  Organic Anion Transporting Polypeptide 1B1: a Genetically Polymorphic Transporter of Major Importance for Hepatic Drug Uptake , 2011, Pharmacological Reviews.

[426]  M. Fromm,et al.  Transporter-Mediated Drug–Drug Interactions with Oral Antidiabetic Drugs , 2011, Pharmaceutics.

[427]  Sang Yup Lee,et al.  Systems metabolic engineering for chemicals and materials. , 2011, Trends in biotechnology.

[428]  C. Cheng,et al.  Drug transporters and blood--testis barrier function. , 2011, The Journal of endocrinology.

[429]  Yibo Wang,et al.  Association of intergenic polymorphism of organic anion transporter 1 and 3 genes with hypertension and blood pressure response to hydrochlorothiazide. , 2011, American journal of hypertension.

[430]  A. Wanner,et al.  Rapid nongenomic actions of inhaled corticosteroids on long-acting β(2)-agonist transport in the airway. , 2011, Pulmonary pharmacology & therapeutics.

[431]  David S. Wishart,et al.  DrugBank 3.0: a comprehensive resource for ‘Omics’ research on drugs , 2010, Nucleic Acids Res..

[432]  Bernhard O. Palsson,et al.  The human metabolic reconstruction Recon 1 directs hypotheses of novel human metabolic functions , 2011, BMC Systems Biology.

[433]  A. Bjorkman,et al.  Drug resistance associated genetic polymorphisms in Plasmodium falciparum and Plasmodium vivax collected in Honduras, Central America , 2011, Malaria Journal.

[434]  P. Roepe.  PfCRT-mediated drug transport in malarial parasites. , 2011, Biochemistry.

[435]  M. Kennedy,et al.  Clinical Implications of Pharmacogenetic Variation on the Effects of Statins , 2011, Drug safety.

[436]  F. Cheng,et al.  Insights into Molecular Basis of Cytochrome P450 Inhibitory Promiscuity of Compounds , 2011, J. Chem. Inf. Model..

[437]  H. Koepsell,et al.  Organic cation transporters (OCTs, MATEs), in vitro and in vivo evidence for the importance in drug therapy. , 2011, Handbook of experimental pharmacology.

[438]  Isabel Roditi,et al.  Genome-wide RNAi screens in bloodstream form trypanosomes identify drug transporters. , 2011, Molecular and biochemical parasitology.

[439]  Oleg Demin,et al.  Integration not isolation: arguing the case for quantitative and systems pharmacology in drug discovery and development. , 2011, Drug discovery today.

[440]  Lin He,et al.  DRAR-CPI: a server for identifying drug repositioning potential and adverse drug reactions via the chemical–protein interactome , 2011, Nucleic Acids Res..

[441]  Rowena E. Martin,et al.  Know your enemy: understanding the role of PfCRT in drug resistance could lead to new antimalarial tactics , 2012, Cellular and Molecular Life Sciences.

[442]  K. Ishibashi,et al.  The evolutionary aspects of aquaporin family. , 2011, American journal of physiology. Regulatory, integrative and comparative physiology.

[443]  Douglas B Kell,et al.  Pharmaceutical drug transport: the issues and the implications that it is essentially carrier-mediated only. , 2011, Drug discovery today.

[444]  Alejandro Sanchez-Flores,et al.  High-throughput phenotyping using parallel sequencing of RNA interference targets in the African trypanosome. , 2011, Genome research.

[445]  John Higgins,et al.  Strategies for bringing drug delivery tools into discovery. , 2011, International journal of pharmaceutics.

[446]  Shiew-Mei Huang,et al.  Transporter‐Mediated Drug–Drug Interactions , 2011, Clinical pharmacology and therapeutics.

[447]  TP Hughes,et al.  OCT‐1 as a Determinant of Response to Antileukemic Treatment , 2011, Clinical pharmacology and therapeutics.

[448]  G. He,et al.  Chemical-protein interactome and its application in off-target identification , 2011, Interdisciplinary Sciences: Computational Life Sciences.

[449]  J. Lima,et al.  Effect of Citrus Juice and SLCO2B1 Genotype on the Pharmacokinetics of Montelukast , 2011, Journal of clinical pharmacology.

[450]  Paul D. Leeson,et al.  Impact of ion class and time on oral drug molecular properties , 2011 .

[451]  Joshua D. Knowles,et al.  Efficient discovery of anti-inflammatory small molecule combinations using evolutionary computing , 2011, Nature chemical biology.

[452]  Lei Xie,et al.  Structure-based systems biology for analyzing off-target binding. , 2011, Current opinion in structural biology.

[453]  A. Tsuji.  Small molecular drug transfer across the blood-brain barrier via carrier-mediated transport systems , 2011, NeuroRX.

[454]  M. Battegay,et al.  Mechanisms of Drug Interactions II: Transport Proteins , 2011 .

[455]  P. Houillier,et al.  The rhesus protein RhCG: a new perspective in ammonium transport and distal urinary acidification. , 2011, Kidney international.

[456]  Tudor I. Oprea,et al.  ChemProt: a disease chemical biology database , 2010, Nucleic Acids Res..

[457]  D. Thwaites,et al.  The SLC36 family of proton‐coupled amino acid transporters and their potential role in drug transport , 2011, British journal of pharmacology.

[458]  Z. Ni,et al.  ATP-binding cassette efflux transporters in human placenta. , 2011, Current pharmaceutical biotechnology.

[459]  Humberto González-Díaz,et al.  2D MI-DRAGON: a new predictor for protein-ligands interactions and theoretic-experimental studies of US FDA drug-target network, oxoisoaporphine inhibitors for MAO-A and human parasite proteins. , 2011, European journal of medicinal chemistry.

[460]  T. Terasaki,et al.  Functional characterization of rat plasma membrane monoamine transporter in the blood-brain and blood-cerebrospinal fluid barriers. , 2011, Journal of pharmaceutical sciences.

[461]  Neema Jamshidi,et al.  Linkage of Organic Anion Transporter-1 to Metabolic Pathways through Integrated “Omics”-driven Network and Functional Analysis* , 2011, The Journal of Biological Chemistry.

[462]  E. Wiemer,et al.  Drug transporters of platinum-based anticancer agents and their clinical significance. , 2011, Drug resistance updates.

[463]  C. Cametti,et al.  On the dielectric relaxation of biological cell suspensions: the effect of the membrane electrical conductivity. , 2011, Colloids and surfaces. B, Biointerfaces.

[464]  Norman W. Paton,et al.  The SuBliMinaL Toolbox: automating steps in the reconstruction of metabolic networks , 2011, J. Integr. Bioinform..

[465]  E. Schneider,et al.  ATP binding cassette systems: structures, mechanisms, and functions , 2011, Central European Journal of Biology.

[466]  E. Ullu,et al.  RNA Interference in Protozoan Parasites: Achievements and Challenges , 2011, Eukaryotic Cell.

[467]  J. Changeux,et al.  X-ray structures of general anaesthetics bound to a pentameric ligand-gated ion channel , 2011, Nature.

[468]  Douglas B Kell,et al.  Genome-wide assessment of the carriers involved in the cellular uptake of drugs: a model system in yeast , 2011, BMC Biology.

[469]  Paul D. Leeson,et al.  The influence of the 'organizational factor' on compound quality in drug discovery , 2011, Nature Reviews Drug Discovery.

[470]  David W. Ritchie,et al.  Using Consensus-Shape Clustering To Identify Promiscuous Ligands and Protein Targets and To Choose the Right Query for Shape-Based Virtual Screening , 2011, J. Chem. Inf. Model..

[471]  Katrin Wlcek,et al.  Organic anion transporting polypeptides (OATPs): regulation of expression and function. , 2011, Current drug metabolism.

[472]  Kim L R Brouwer,et al.  Influence of drug transport proteins on the pharmacokinetics and drug interactions of HIV protease inhibitors. , 2011, Journal of pharmaceutical sciences.

[473]  Neil Benson,et al.  Systems Pharmacology: Bridging Systems Biology and Pharmacokinetics-Pharmacodynamics (PKPD) in Drug Discovery and Development , 2011, Pharmaceutical Research.

[474]  G. Stewart.  The emerging physiological roles of the SLC14A family of urea transporters , 2011, British journal of pharmacology.

[475]  Xiyan Li,et al.  Metabolites as global regulators: A new view of protein regulation , 2011, BioEssays : news and reviews in molecular, cellular and developmental biology.

[476]  M. Fanselow,et al.  Inhaled Anesthetic Responses of Recombinant Receptors and Knockin Mice Harboring α2(S270H/L277A) GABAA Receptor Subunits That Are Resistant to Isoflurane , 2011, Journal of Pharmacology and Experimental Therapeutics.

[477]  H. Bayley,et al.  Controlled translocation of individual DNA molecules through protein nanopores with engineered molecular brakes. , 2011, Nano letters.

[478]  F. Theodoulou,et al.  Mammalian peroxisomal ABC transporters: from endogenous substrates to pathology and clinical significance , 2011, British journal of pharmacology.

[479]  D. Kell.  Systems biology: Metabolites do social networking. , 2011, Nature chemical biology.

[480]  Joseph J. Babcock,et al.  Activation of human ether-a-go-go related gene (hERG) potassium channels by small molecules , 2011, Acta Pharmacologica Sinica.

[481]  Y. Shitara.  Clinical importance of OATP1B1 and OATP1B3 in drug-drug interactions. , 2011, Drug metabolism and pharmacokinetics.

[482]  C. Cheng,et al.  Emerging role for drug transporters at the blood-testis barrier. , 2011, Trends in pharmacological sciences.

[483]  K. Maeda,et al.  Prediction of the Overall Renal Tubular Secretion and Hepatic Clearance of Anionic Drugs and a Renal Drug-Drug Interaction Involving Organic Anion Transporter 3 in Humans by In Vitro Uptake Experiments , 2011, Drug Metabolism and Disposition.

[484]  Ronan M. T. Fleming,et al.  Quantitative prediction of cellular metabolism with constraint-based models: the COBRA Toolbox v2.0 , 2007, Nature Protocols.

[485]  D. Singh,et al.  Mechanism of Amphotericin B Resistance in Clinical Isolates of Leishmania donovani , 2011, Antimicrobial Agents and Chemotherapy.

[486]  R. Kim,et al.  Environmental and Genetic Factors Affecting Transport of Imatinib by OATP1A2 , 2011, Clinical pharmacology and therapeutics.

[487]  C. Haller,et al.  Adverse Drug Reactions: Moving from Chance to Science , 2011, Clinical pharmacology and therapeutics.

[488]  S. Pukatzki,et al.  Antibiotic resistance mechanisms of Vibrio cholerae. , 2011, Journal of medical microbiology.

[489]  Y. Choi,et al.  Herb-drug interactions: Focus on metabolic enzymes and transporters , 2011, Archives of pharmacal research.

[490]  Seth I. Berger,et al.  Role of systems pharmacology in understanding drug adverse events , 2011, Wiley interdisciplinary reviews. Systems biology and medicine.

[491]  A. Dalpiaz,et al.  Prodrugs and endogenous transporters: are they suitable tools for drug targeting into the central nervous system? , 2011, Current pharmaceutical design.

[492]  J. Palomino,et al.  Efflux as a mechanism for drug resistance in Mycobacterium tuberculosis. , 2011, FEMS immunology and medical microbiology.

[493]  N. Meanwell.  Improving drug candidates by design: a focus on physicochemical properties as a means of improving compound disposition and safety. , 2011, Chemical research in toxicology.

[494]  Bonaventura Clotet,et al.  Drug uptake transporters in antiretroviral therapy. , 2011, Pharmacology & therapeutics.

[495]  T. Nakanishi,et al.  Solute carrier transporters as targets for drug delivery and pharmacological intervention for chemotherapy. , 2011, Journal of pharmaceutical sciences.

[496]  J. König,et al.  Double‐transfected MDCK cells expressing human OCT1/MATE1 or OCT2/MATE1: determinants of uptake and transcellular translocation of organic cations , 2011, British journal of pharmacology.

[497]  Ruth Brenk,et al.  Mining the ChEMBL Database: An Efficient Chemoinformatics Workflow for Assembling an Ion Channel-Focused Screening Library , 2011, J. Chem. Inf. Model..

[498]  Tudor I. Oprea,et al.  Linking Pharmacology to Clinical Reports: Cyclobenzaprine and Its Possible Association With Serotonin Syndrome , 2011, Clinical pharmacology and therapeutics.

[499]  T. Terasaki,et al.  Diphenhydramine active uptake at the blood-brain barrier and its interaction with oxycodone in vitro and in vivo. , 2011, Journal of pharmaceutical sciences.

[500]  Bryan L Roth,et al.  Strategies to discover unexpected targets for drugs active at G protein-coupled receptors. , 2011, Annual review of pharmacology and toxicology.

[501]  Tudor I. Oprea,et al.  Associating Drugs, Targets and Clinical Outcomes into an Integrated Network Affords a New Platform for Computer‐Aided Drug Repurposing , 2011, Molecular informatics.

[502]  P. Pohl,et al.  Intrinsic CO2 permeability of cell membranes and potential biological relevance of CO2 channels. , 2011, Chemphyschem : a European journal of chemical physics and physical chemistry.

[503]  Michael S Lajiness,et al.  Systems chemical biology and the Semantic Web: what they mean for the future of drug discovery research. , 2012, Drug discovery today.

[504]  Tudor I. Oprea,et al.  Improving the prediction of the brain disposition for orally administered drugs using BDDCS. , 2012, Advanced drug delivery reviews.

[505]  D. Sibley,et al.  The Blood-Testis Barrier and Its Implications for Male Contraception , 2012, Pharmacological Reviews.

[506]  Horst Kessler,et al.  Intestinal permeability of cyclic peptides: common key backbone motifs identified. , 2012, Journal of the American Chemical Society.

[507]  B. Hagenbuch,et al.  OATPs, OATs and OCTs: the organic anion and cation transporters of the SLCO and SLC22A gene superfamilies , 2012, British journal of pharmacology.

[508]  Ruedi Aebersold,et al.  Direct identification of ligand-receptor interactions on living cells and tissues , 2012, Nature Biotechnology.

[509]  Juliana M. Sá,et al.  Functional Characterization of the Plasmodium falciparum Chloroquine-Resistance Transporter (PfCRT) in Transformed Dictyostelium discoideum Vesicles , 2012, PloS one.

[510]  J. Venitz,et al.  Fluoroquinolone disposition: identification of the contribution of renal secretory and reabsorptive drug transporters , 2012, Expert opinion on drug metabolism & toxicology.

[511]  A. Goffeau,et al.  Yeast ATP-binding cassette transporters conferring multidrug resistance. , 2012, Annual review of microbiology.

[512]  S. Bates,et al.  Transporter pharmacogenetics: transporter polymorphisms affect normal physiology, diseases, and pharmacotherapy. , 2012, Discovery medicine.

[513]  T. Dinan,et al.  Inhibition of P‐glycoprotein enhances transport of imipramine across the blood–brain barrier: microdialysis studies in conscious freely moving rats , 2012, British journal of pharmacology.

[514]  I. Tamai.  Oral drug delivery utilizing intestinal OATP transporters. , 2012, Advanced drug delivery reviews.

[515]  David S. Roos,et al.  TDR Targets: a chemogenomics resource for neglected diseases , 2011, Nucleic Acids Res..

[516]  Alberto Del Rio,et al.  Freely accessible databases of commercial compounds for high- throughput virtual screenings. , 2012, Current topics in medicinal chemistry.

[517]  B. Feng,et al.  Physiologically Based Modeling of Pravastatin Transporter-Mediated Hepatobiliary Disposition and Drug-Drug Interactions , 2012, Pharmaceutical Research.

[518]  G. Ecker,et al.  Evidence-based approach to assess passive diffusion and carrier-mediated drug transport. , 2012, Drug discovery today.

[519]  Lihong Liu,et al.  Modern methods for delivery of drugs across the blood-brain barrier. , 2012, Advanced drug delivery reviews.

[520]  P. Couraud,et al.  The involvement of a Na⁺- and Cl⁻-dependent transporter in the brain uptake of amantadine and rimantadine. , 2012, Molecular pharmaceutics.

[521]  Bruno Hagenbuch,et al.  The expression and function of organic anion transporting polypeptides in normal tissues and in cancer. , 2012, Annual review of pharmacology and toxicology.

[522]  Norbert Perrimon,et al.  RNAi screening: new approaches, understandings, and organisms , 2012, Wiley interdisciplinary reviews. RNA.

[523]  Olivier Fardel,et al.  Environmental chemicals as substrates, inhibitors or inducers of drug transporters: implication for toxicokinetics, toxicity and pharmacokinetics , 2012, Expert opinion on drug metabolism & toxicology.

[524]  H. Glaeser,et al.  Interaction of innovative small molecule drugs used for cancer therapy with drug transporters , 2012, British journal of pharmacology.

[525]  Patrick R. Griffin,et al.  PubChem promiscuity: a web resource for gathering compound promiscuity data from PubChem , 2012, Bioinform..

[526]  Mathias Dunkel,et al.  Binding sites in membrane proteins--diversity, druggability and prospects. , 2012, European journal of cell biology.

[527]  Cui Yang,et al.  Physiological and Pharmacological Roles of Vascular Nucleoside Transporters , 2012, Journal of cardiovascular pharmacology.

[528]  V. Kouznetsova,et al.  Organic Anion and Cation SLC22 “Drug” Transporter (Oat1, Oat3, and Oct1) Regulation during Development and Maturation of the Kidney Proximal Tubule , 2012, PloS one.

[529]  [System biology and synthetic biology modify drug discovery and development]. , 2012, Medecine sciences : M/S.

[530]  O. Taboureau,et al.  The impact of network biology in pharmacology and toxicology , 2012, SAR and QSAR in environmental research.

[531]  M. Pirmohamed,et al.  Lamotrigine is a substrate for OCT1 in brain endothelial cells. , 2012, Biochemical pharmacology.

[532]  David W Ritchie,et al.  Identifying and characterizing promiscuous targets: Implications for virtual screening , 2012, Expert opinion on drug discovery.

[533]  P. Neuvonen.  Towards safer and more predictable drug treatment--reflections from studies of the First BCPT Prize awardee. , 2012, Basic & clinical pharmacology & toxicology.

[534]  W. Banks.  Drug delivery to the brain in Alzheimer's disease: consideration of the blood-brain barrier. , 2012, Advanced drug delivery reviews.

[535]  K. Maeda,et al.  Transporter‐Mediated Drug–Drug Interactions Involving OATP Substrates: Predictions Based on In Vitro Inhibition Studies , 2012, Clinical pharmacology and therapeutics.

[536]  Wolfgang Guba,et al.  Can we discover pharmacological promiscuity early in the drug discovery process? , 2012, Drug discovery today.

[537]  Yang Song,et al.  Therapeutic target database update 2012: a resource for facilitating target-oriented drug discovery , 2011, Nucleic Acids Res..

[538]  Sean Ekins,et al.  Molecular Determinants of Ligand Selectivity for the Human Multidrug and Toxin Extruder Proteins MATE1 and MATE2-K , 2012, Journal of Pharmacology and Experimental Therapeutics.

[539]  H. Barton,et al.  In Vitro Evaluation of Hepatic Transporter-Mediated Clinical Drug-Drug Interactions: Hepatocyte Model Optimization and Retrospective Investigation , 2012, Drug Metabolism and Disposition.

[540]  Ulf Norinder,et al.  Classification of Inhibitors of Hepatic Organic Anion Transporting Polypeptides (OATPs): Influence of Protein Expression on Drug–Drug Interactions , 2012, Journal of medicinal chemistry.

[541]  L. Tremaine,et al.  Impact of drug transporter pharmacogenomics on pharmacokinetic and pharmacodynamic variability – considerations for drug development , 2012, Expert opinion on drug metabolism & toxicology.

[542]  A. Rostami-Hodjegan,et al.  Physiologically Based Pharmacokinetics Joined With In Vitro–In Vivo Extrapolation of ADME: A Marriage Under the Arch of Systems Pharmacology , 2012, Clinical pharmacology and therapeutics.

[543]  C. Ehrhardt,et al.  Organic cation transporters in the blood-air barrier: expression and implications for pulmonary drug delivery. , 2012, Therapeutic delivery.

[544]  W. Geldenhuys,et al.  The blood-brain barrier choline transporter. , 2012, Central nervous system agents in medicinal chemistry.

[545]  Taizo Shiraishi,et al.  Human equilibrative nucleoside transporter 1 expression is a strong independent prognostic factor in UICC T3–T4 pancreatic cancer patients treated with preoperative gemcitabine-based chemoradiotherapy , 2012, Journal of hepato-biliary-pancreatic sciences.

[546]  S. Husain,et al.  The Location and Nature of General Anesthetic Binding Sites on the Active Conformation of Firefly Luciferase; A Time Resolved Photolabeling Study , 2012, PloS one.

[547]  O. Pantoja.  High Affinity Ammonium Transporters: Molecular Mechanism of Action , 2012, Front. Plant Sci..

[548]  C. Sempoux,et al.  Human equilibrative nucleoside transporter 1 (hENT1) expression is a potential predictive tool for response to gemcitabine in patients with advanced cholangiocarcinoma. , 2012, European journal of cancer.

[549]  Gergely Zahoránszky-Köhalmi,et al.  Drug Effect Prediction by Polypharmacology-Based Interaction Profiling , 2012, J. Chem. Inf. Model..

[550]  Igor Goryanin,et al.  The reconstruction and analysis of tissue specific human metabolic networks. , 2012, Molecular bioSystems.

[551]  A. Ferro,et al.  Comparative Pharmacokinetics and Pharmacodynamics of Platelet Adenosine Diphosphate Receptor Antagonists and their Clinical Implications , 2012, Clinical Pharmacokinetics.

[552]  Mark C. Field,et al.  High-throughput decoding of anti-trypanosomal drug efficacy and resistance , 2011, Nature.

[553]  John P. Overington,et al.  ChEMBL: a large-scale bioactivity database for drug discovery , 2011, Nucleic Acids Res..

[554]  D. Surry,et al.  Prediction of the in vivo OATP1B1-mediated drug-drug interaction potential of an investigational drug against a range of statins. , 2012, European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences.

[555]  B. Kemp,et al.  The Ancient Drug Salicylate Directly Activates AMP-Activated Protein Kinase , 2012, Science.

[556]  A. Mardinoğlu,et al.  Systems medicine and metabolic modelling , 2012, Journal of internal medicine.

[557]  A. Sparreboom,et al.  Contribution of tumoral and host solute carriers to clinical drug response. , 2012, Drug resistance updates : reviews and commentaries in antimicrobial and anticancer chemotherapy.

[558]  A. Mitra,et al.  Sodium dependent multivitamin transporter (SMVT): a potential target for drug delivery. , 2012, Current drug targets.

[559]  K. Giacomini,et al.  The UCSF‐FDA TransPortal: A Public Drug Transporter Database , 2012, Clinical pharmacology and therapeutics.

[560]  A. Ray,et al.  Renal drug–drug interactions: what we have learned and where we are going , 2012, Expert opinion on drug metabolism & toxicology.

[561]  Paul O'Shea.  Future medicine shaped by an interdisciplinary new biology , 2012, The Lancet.

[562]  Dong Xu,et al.  Protein Databases on the Internet , 2012, Current protocols in molecular biology.

[563]  P. Sexton,et al.  Drug transporters in drug efficacy and toxicity. , 2012, Annual review of pharmacology and toxicology.

[564]  W. Geldenhuys,et al.  Novel models for assessing blood–brain barrier drug permeation , 2012, Expert opinion on drug metabolism & toxicology.

[565]  Michael J. Keiser,et al.  Large Scale Prediction and Testing of Drug Activity on Side-Effect Targets , 2012, Nature.

[566]  J. Brockmöller,et al.  The prototypic pharmacogenetic drug debrisoquine is a substrate of the genetically polymorphic organic cation transporter OCT1. , 2012, Biochemical pharmacology.

[567]  E. van de Steeg,et al.  Functions of OATP1A and 1B transporters in vivo: insights from mouse models. , 2012, Trends in pharmacological sciences.

[568]  J. Haiech,et al.  Biologie des systèmes et ingénierie biologique modifient la découverte et le développement des médicaments , 2012 .

[569]  R. Altman,et al.  Data-Driven Prediction of Drug Effects and Interactions , 2012, Science Translational Medicine.

[570]  T. Nakanishi,et al.  Genetic polymorphisms of OATP transporters and their impact on intestinal absorption and hepatic disposition of drugs. , 2012, Drug metabolism and pharmacokinetics.

[571]  Lourdes Cucurull-Sanchez,et al.  Relevance of systems pharmacology in drug discovery. , 2012, Drug discovery today.

[572]  N. Cherrington,et al.  Genetics or environment in drug transport: the case of organic anion transporting polypeptides and adverse drug reactions , 2012, Expert opinion on drug metabolism & toxicology.

[573]  Andrew C Good,et al.  Implications of promiscuous Pim-1 kinase fragment inhibitor hydrophobic interactions for fragment-based drug design. , 2012, Journal of medicinal chemistry.

[574]  Philip E. Bourne,et al.  SuperTarget goes quantitative: update on drug–target interactions , 2011, Nucleic Acids Res..

[575]  Sean Ekins,et al.  A substrate pharmacophore for the human organic cation/carnitine transporter identifies compounds associated with rhabdomyolysis. , 2012, Molecular pharmaceutics.

[576]  Sarah L. Kinnings,et al.  Novel computational approaches to polypharmacology as a means to define responses to individual drugs. , 2012, Annual review of pharmacology and toxicology.

[577]  R. Iyengar,et al.  Systems pharmacology: network analysis to identify multiscale mechanisms of drug action. , 2012, Annual review of pharmacology and toxicology.

[578]  Yuko Ohno,et al.  Pharmacophore modeling for hERG channel facilitation. , 2012, Biochemical and biophysical research communications.

[579]  M. Barrett,et al.  Aquaglyceroporin 2 controls susceptibility to melarsoprol and pentamidine in African trypanosomes , 2012, Proceedings of the National Academy of Sciences.

[580]  A. Ayrton,et al.  Hydrophilic anti-migraine triptans are substrates for OATP1A2, a transporter expressed at human blood-brain barrier , 2012, Xenobiotica; the fate of foreign compounds in biological systems.

[581]  K. Asami.  Dielectric spectroscopy reveals nanoholes in erythrocyte ghosts , 2012 .

[582]  Kevan M. Shokat,et al.  Chemical genetic discovery of targets and anti-targets for cancer polypharmacology , 2012, Nature.

[583]  Human Equilibrative Nucleoside Transporter 1 Expression Predicts Survival of Advanced Cholangiocarcinoma Patients Treated With Gemcitabine-Based Adjuvant Chemotherapy After Surgical Resection , 2012, Annals of surgery.

[584]  A Rostami-Hodjegan,et al.  Absolute abundance and function of intestinal drug transporters: a prerequisite for fully mechanistic in vitro-in vivo extrapolation of oral drug absorption. , 2013, Biopharmaceutics & drug disposition.

[585]  Drug Resistance in Leishmania , 2014 .